Is it safe?
Can ANIP take a bad year?
ANI Pharmaceuticals, Inc. holds $5.9M more cash than debt, so a bad year is a question about profits, not about lenders.
$5.9M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 2.50
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 3.87×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ1 2026
- $305M
- Cash and short-term investments
- $311M
- Net cash
- $5.9M
- EBITDA, trailing twelve months
- $213M
- Operating profit, trailing twelve months
- $124M
- Debt / equity
- 0.54×
- Total debt / EBITDA
- 1.43×
- Annualised volatilitytwo years of daily moves
- 37%
- Worst drawdown on file
- −73%
- Below its 52-week high
- −25%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - Specialty & Generic
Ranks #10 of 28 by Smart Score